Stocks kicked off a pivotal week on an upbeat note, boosted by some blue-chip mergers and acquisitions news and a buoyant reading on consumer expectations.
Mostly, however, Monday was a "wait-and-see" session. After all, tomorrow's critical reading on inflation and an interest rate announcement from the Federal Reserve later this week are certain to shape where stocks go next.
The best Dow dividend stocks never go out of style, and on Monday two of them contributed to a big day for M&A news. Amgen (AMGN), which deserves a place in just about any portfolio of top biotech stocks, struck an agreement to buy Horizon Therapeutics (HZNP) for $28.3 billion, including debt. The biggest healthcare deal of 2022 gives Amgen control of Horizon’s treatments for rare autoimmune and inflammatory diseases, including Tepezza, a blockbuster drug for thyroid eye disease.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Meanwhile, Dow stock Microsoft (MSFT), which routinely ranks as a top stock pick for billionaires and hedge funds alike, struck a 10-year partnership deal with London Stock Exchange Group (LNSTY). The cloud-computing giant, which acquired a 4% stake in the bourse operator, will provide LSE with next-generation infrastructure, data and analytics.
In economic news, a survey by the Federal Reserve Bank of New York showed that regular folks are feeling better about both the future path of inflation and income growth. Consumers' expectations for inflation over the next one, three and five years decreased smartly, the NY Fed reported. At the same time, expectations for income growth reached a series high.
At the end of the day, markets finished the session with broad-based gains. The blue-chip Dow Jones Industrial Average added 1.6% to finish at 34,004, while the broader S&P 500 rose 1.4% to close at 3,990. The tech-heavy Nasdaq Composite gained 1.3% to reach 11,143.
November's Inflation Report: What to Expect
All eyes are on the last inflation report of 2022, slated for release before Tuesday's opening bell – and just a day before the Federal Reserve's final interest rate decision of the year.
A nasty upside surprise in CPI could complicate the central bank's calculus, and even send stocks into a tizzy. To get a sense of what the experts think about tomorrow's inflation report, have a look at what economists, strategists and other market pros have to say about the pending CPI print.
-
My Three-Day Rule for Investing: And If it Applies NowStock Market I've seen a lot in my career. Here's what I see now in the stock market.
-
Is It Time to Invest in Europe?Stock Market Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
-
Fed Leaves Rates Unchanged: What the Experts Are SayingFederal Reserve As widely expected, the Federal Open Market Committee took a 'wait-and-see' approach toward borrowing costs.
-
Fed Sees Fewer Rate Cuts in 2025: What the Experts Are Saying
Federal Reserve The Federal Reserve cut interest rates as expected, but the future path of borrowing costs became more opaque.
-
Why Is Warren Buffett Selling So Much Stock?Berkshire Hathaway is dumping equities, hoarding cash and making market participants nervous.
-
Fed Cuts Rates Again: What the Experts Are Saying
Federal Reserve The central bank continued to ease, but a new administration in Washington clouds the outlook for future policy moves.
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have TodayGoogle parent Alphabet has been a market-beating machine for ages.
-
Fed Goes Big With First Rate Cut: What the Experts Are Saying
Federal Reserve A slowing labor market prompted the Fed to start with a jumbo-sized reduction to borrowing costs.
